a-cgrp, rat

Endogenous neuropeptide, potent vasodilator

α-CGRP (rat) acetate is a calcitonin gene-related peptide (CGRP). CGRP (rat) acetate is a potent vasodilator.

PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and 5-HT1F Receptor partial agonist (EC50 = 77.91 nM). It demonstrates significant efficacy in rat models of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins while inhibiting the phosphorylation levels of ERK and CREB. This compound is useful for migraine research.

Tyr-α-CGRP (rat) is an N-terminally tyrosinated analog of the neuropeptide α-CGRP that induces a fall in resting tension of isolated opossum internal anal sphincter (IAS) with an EC50 value of 178 nM.

α-CGRP, rat TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP, rat TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP, rat TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies [1] [2] [3] .

Calcitonin Gene-Related Peptide (CGRP) II, rat TFA, functions as a potent and enduring vasodilator by activating CGRP receptors. This compound is utilized in cardiovascular disease research [1].

[Tyr22] Calcitonin Gene Related Peptide (22-37), rat, refers to a fragment (amino acids 22-37) of the rat calcitonin gene-related peptide (CGRP) that targets the CGRP receptor and adenylate cyclase. While calcitonin is primarily produced by thyroid C cells, CGRP is predominantly secreted and stored within the nervous system [1].

Fremanezumab (TEV-48125) is a humanised monoclonal antibody targeting CGRP, capable of neutralising human (IC50=7.94 nM), mouse (IC50=19.6 nM) and rat CGRP, and is indicated for the prevention of migraine. Fremanezumab inhibits CGRP's vasodilatory effects in the basilar artery constriction segment and suppresses activation of A-δ and high-threshold (HT) neurons in the meningeal nociceptive system triggered by cortical spreading depression (CSD) in rats. In vitro, Fremanezumab counteracts CGRP's immunosuppressive effects on microglia and lymphocytes.

α-CGRP (mouse, rat) TFA, a neuropeptide belonging to the calcitonin gene-related peptide (CGRP) family, is predominantly located at neuromuscular junctions and functions as a potent vasodilator. Peripheral administration of α-CGRP (mouse, rat) TFA may result in decreased blood pressure and elevated heart rate, in addition to the relaxation of colonic smooth muscle. This compound shows promising utility in the investigation of cardiovascular, pro-inflammatory, migraine, and metabolic conditions [1] [2] [3].

Rat CGRP-(8-37) (VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF) is a highly selective CGRP receptor antagonist

CGRP (83-119), rat TFA (Calcitonin Gene Related Peptide(83-119), rat TFA) is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor.

Calcitonin Gene Related Peptide (CGRP) II, rat (TFA) is a neuropeptide with 37 amino acid.

Calcitonin Gene Related Peptide (CGRP) (83-119), rat is a 37 amino acid calcitonin family of neuropeptide, acts through calcitonin receptor-like receptor.

CGRP 8-37 (rat) is a CGRP receptor antagonist, a CGRP fragment with potential anti-injury effects that induces arterial relaxation.

Calcitonin Gene Related Peptide (CGRP) (83-119), rat, is a neuropeptide from the calcitonin family composed of 37 amino acids, and it functions through (CRLR).

Calcitonin Gene Related Peptide (CGRP) (83-119), rat (TFA), is a neuropeptide from the calcitonin family composed of 37 amino acids and functions via (CRLR).